In the News | Friends of Cancer Research

You are here

In the News

May 25, 2019
ASCO recently announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force... Read more
May 22, 2019
Executive Summary Academic institutions confused about agency standards are overly cautious in requiring early-phase studies be conducted under full GMPs, experts say; CBER Director Marks highlights... Read more
May 21, 2019
Executive Summary While the US FDA works to cut time necessary to approve expanded access applications, sponsors are creating delays by mandating patients and institutions sign contracts to gain... Read more
May 20, 2019
Although study findings have identified tumor mutational burden (TMB) as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing... Read more
May 20, 2019
Two in­flu­en­tial non­prof­its fo­cused on can­cer drug R&D are urg­ing the FDA to take a more flex­i­ble ap­proach to clin­i­cal work to help triage an in­flux of new cell and gene can­cer ther... Read more
May 20, 2019
A new white paper from the Friends of Cancer Research (FOCR) and the Parker Institute for Cancer Immunotherapy calls on the US Food and Drug Administration (FDA) to ease clinical and manufacturing... Read more
May 17, 2019
A risk-averse culture at universities and cancer centers holds back a field of potentially life-saving cell transplantation therapies, scientists said.   “Patients are waiting. These therapies are... Read more
May 15, 2019
NIH concerns slammed the brakes on a bill May 15 seeking more transparency about people serving on federal advisory boards.   The Senate Homeland Security and Governmental Affairs Committee agreed to... Read more
May 14, 2019
The US National Institutes of Health opposes a bill wending its way through Congress aimed at making government advisory committees more transparent, Science reports.   At hand, it says, is the 1972... Read more
May 14, 2019
As Congress considers comprehensive reforms to the regulatory paradigm for all in vitro clinical tests (IVCTs), including LDTs, recent developments are highlighting the limitations of FDA’s current... Read more

Pages